Sector Expert: Edward Lanphier
Edward Lanphier, chair of the Alliance for Regenerative Medicine, is also the founder of Sangamo BioSciences Inc. He has served as president, CEO and as a member of the board of directors since Sangamo's inception in 1995. Mr. Lanphier has more than 30 years of experience in the pharmaceutical and biotechnology industry. From June 1992 to May 1997, he held various positions at Somatix Therapy Corp., a gene therapy company, including executive vice president, commercial development and chief financial officer. Prior to Somatix, he was president and CEO of BioGrowth Inc., a biotechnology company that merged with Celtrix Laboratories to form Celtrix Pharmaceuticals Inc. in 1991. From 1986 to 1987, he served as vice president of corporate development at Biotherapeutics, Inc. From 1984 to 1986 Mr. Lanphier served as vice president of corporate development at Synergen Inc. Prior to Synergen, he was employed by Eli Lilly and Company, in the strategic business planning biotechnology group. He currently serves on the board of directors of the Biotechnology Institute, the board of directors and as a member of the Executive Committee of the Alliance for Regenerative Medicine, the board of trustees for The Buck Institute for Research on Aging, and the Dean's Advisory Board for the University of Michigan School of Public Health. Mr. Lanphier holds a bachelor's degree in biochemistry from Knox College.
How ARM's Edward Lanphier Is Fighting for Cell Therapy Cures that Save Patients and Portfolios (3/19/15)
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still loom on the political and reimbursement front. Edward Lanphier, founder and CEO of Sangamo BioSciences Inc. and current chairman of the Alliance for Regenerative Medicine, sees near-term milestones on the horizon, as well as additional inflows of validating capital from prominent investors. In this interview with The Life Sciences Report, Lanphier describes upcoming milestones and share-moving catalysts, some of which will be revealed at ARM's Regen Med Investor Day.